Prevalence of concomitant medications in older HIV+ patients and comparison with general population

Figures & data

Table 1. Characteristics of HIV-infected population ≥ 50 years old.

	n = 118
Sex	%(n)
Men	77.1 (91)
Women	22.9 (27)
Age
Age (mean, standard deviation)	59.9 (6.3)
Age (median, range)	54.8 (50.0–77.7)
	%(n)
50–54 years	50.8 (60)
55–59 years	26.3 (31)
60–64 years	8.5 (10)
65–70 years	10.2 (12)
>70 years	4.2 (5)
Country of origin	%(n)
Spain	83.9 (99)
Other	13.6 (16)
Unknown	2.5 (3)
Years since diagnosis^a
Mean (standard deviation)	13.6 (6.76)
Median (range)	13.4 (0.55–28)
ART	%(n)
PI/r-based	53.4 (63)
NNRTI-based	41.5 (49)
Others	5.1 (6)
VL at the end of the study^a	%(n)
< 50 copies/ml	88.0 (103)
50-200 copies/ml	2.6 (3)
>200 copies/ml	6.0 (7)
Not evaluable (naive)	3.4 (4)
CD4 at the end of the study^a	%(n)
< 200 cells/ml	6.8 (8)
200-349 cells/ml	17.1 (20)
350-500 cells/ml	16.2 (19)
>500 cells/ml	56.4 (66)
Not evaluable (naive)	3.4 (4)
Hepatitis C	%(n)
Yes	28.0 (33)
No	68.6 (81)
Unknown	3.4 (4)

ART: antiretroviral therapy; PI: protease inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitors; VL: viral load; HIV: human immunodeficiency virus

a: n = 117.

Figure 1. Number of concomitant medications taken by human immunodeficiency virus (HIV)-positive patients ≥ 50 years old.

Figure 2. Median days of treatment (defined daily dose, DDD), by patient, for each Anatomical Therapeutic Chemical (ATC) classification medication subgroup for human immunodeficiency virus (HIV)-positive patients ≥ 50 years old.

Figure 3. Percentage of 50–64 year-old males in the general population and in human immunodeficiency virus (HIV)-infected population, (included therapeutic subgroups prescribed for more than 10 HIV-positive patients).

*Statistically significant differences.